Abstract: Provided herein are methods for treating melanoma in a subject.

Abstract: Embodiments may provide a cache for query results that can adapt the cache-space utilization to the popularity of the various topics represented in the query stream. For example, a method for query processing may perform receiving a plurality of queries for data and requesting data responsive to at least one query from a data cache comprising a temporal cache, wherein the temporal cache is configured to store data based on a topic associated with the data and is configured to retrieve data based on a topic, and wherein the data cache is configured to retrieve data responsive to at least one query from the computer system.

Abstract: Embodiments may provide a cache for query results that can adapt the cache-space utilization to the popularity of the various topics represented in the query stream. For example, a method for query processing may perform receiving a plurality of queries for data, determining at least one topic associated with each query, and requesting data responsive to each query from a data cache comprising a plurality of partitions, including at least a static cache partition, a dynamic cache partition, and a temporal cache partition, the temporal cache partition may store data based on a topic associated with the data, and may be further partitioned into a plurality of topic portions, each portion may store data relating to an associated topic, wherein the associated topic may be selected from among determined topics of queries received by the computer system, and the data cache may retrieve data for the queries from the computer system.

Abstract: The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's meta-bolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: A method for generating hypotheses in a corpus of data comprises selecting a form of ontology; coding the corpus of data based on the form of the ontology; generating ontology space based on coding results and the ontology; transforming the ontology space into a hypothesis space by grouping hypotheses; weighing hypotheses included in the hypothesis space; and applying a science-based optimization algorithm configured to model a science-based treatment of the weighted hypotheses.

Abstract: Small molecule carbazole compounds for use as androgen receptor inhibitors are provided herein. Also provided herein are methods for using the carbazole compounds in treating prostate cancer, including castration-resistant prostate cancer and enzalutamide-resistant prostate cancer. The methods include administering to a subject an effective amount of a compound or composition as described herein.

Abstract: Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin ?-4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.

Abstract: Methods of transplanting target cells into a subject in need thereof. The methods generally comprise creating a sealed transplantation space by attaching an acellular membrane to the surface of a visceral organ or tissue in the subject in a manner such that a sealed space is created between the surface of the visceral organ or tissue and the membrane, and inserting a mixture of support cells and the target cells into the sealed transplantation space.

Abstract: Disclosed herein are methods of synthesizing mahanine and related compounds. The synthesis features an intramolecular aryl-alkyne isomerization, transition metal catalyzed cross-coupling and intramolecular carbazole forming reaction.

Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.

Abstract: A rotating dual-electrode infrared cell for in situ electrochemical attenuated-total-reflection infrared spectroscopy (ATR-IRS) comprising: a first and second prism; a first and second thin metal film, wherein the first thin metal film is coated on a surface of the first prism and the second thin metal film is coated on a surface of the second prism; an ion exchange membrane; and a first and second cell body, wherein each cell body comprises an inlet and outlet.

Abstract: Provided are in vitro serologic methods of assessing the presence of, and assessing the progression of, liver fibrosis in a subject. Also provided are methods of assessing efficacy of an agent for the treatment of liver fibrosis, and methods of treating liver fibrosis. The methods involve quantitatively measuring di-sialylated and mono-sialylated O-glycoforms of a peptide fragment of hemopexin (HPX) in a test serum sample obtained from a test subject, and comparing the measured amounts of di-sialylated and mono-sialylated O-glycoforms of the peptide fragment of hemopexin to a reference amount. In certain embodiments, the measuring is performed using LC-MS/MS-MRM (liquid chromatography/tandem mass spectrometry/multiple reaction monitoring). In certain embodiments, the measuring is performed using LC/MS3 (liquid chromatography with triple-stage mass spectrometric detection).

Abstract: Devices including graphene quantum dots yield extremely high performance THz bolometers, by measuring the current of hot electrons formed in the graphene source and drain electrodes of the device and propagating through the graphene quantum dot connected thereto. Devices may also include additional materials such as MoS2, as well as one or more gate electrodes to alter performance as needed.

Abstract: Technologies are disclosed for computing heavy hitter histograms using locally private randomization. Under this strategy, “agents” can each hold a “type” derived from a large dictionary. By performing an algorithm, an estimate of the distribution of data can be obtained. Two algorithms implement embodiments for performing methods involving differential privacy for one or more users, and usually are run in the local model. This means that information is collected from the agents with added noise to hide the agents' individual contributions to the histogram. The result is an accurate enough estimate of the histogram for commercial or other applications relating to the data collection of one or more agents. Specifically, the proposed algorithms improve on the performance (measured in computation and memory requirements at the server and the agent, as well as communication volume) of previously solutions.

Abstract: The present invention relates to markers and therapeutic targets of abnormal retinal pigment epithelium (RPE).

Abstract: A system for producing dry nanoparticles from a liquid includes a closed tubing system which incorporates a mister, heater and an electrostatic collector therein. The system is able to produce dry nanoparticles from liquid-suspensions and from solvent solutions.

Abstract: A method and system for contact tracing and alerting anonymously tracks persons within and across digitally modeled areas using registration stations within the area having scannable digital codes which are unique to the area. Upon being alerted to a contagion situation, either from a laboratory or from an area administrator, the system compares electronic visit tickets unique to each person's visit to determine overlap and generates at least one of an exposure event notifications and a contamination event notifications responsive to one or more determinations made by the comparing.

Abstract: The present invention is directed towards methods of culturing non-keratinocyte epithelial cells, with the methods comprising culturing non-keratinocyte epithelial cells in the presence of feeder cells and a calcium-containing medium while inhibiting the activity of Rho kinase (ROCK) in the feeder cell, the non-keratinocyte epithelial cells or both during culturing.

Abstract: Embodiments of the present systems and methods may provide techniques to predict the success or failure of a drug used for disease treatment. For example, a method of determining drug efficacy may include, for a plurality of patients, generating a directed acyclic graph from health related information of each patient comprising nodes representing a medical event of the patient, at least one first edge connecting the first node to an additional node, each additional edge connecting nodes representing two consecutive medical events, the edge having a weight based on a time difference between the two consecutive medical events, capturing a plurality of features from each directed acyclic graph, generating a binary graph classification model on captured features of each directed acyclic graph, determining a probability that a drug or treatment will be effective using the binary graph classification model, and determining a drug to be prescribed to a patient based on the determined probability.